Deciphera Pharmaceuticals (DCPH) Tops Q4 EPS by 5c

Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q4 EPS of ($0.54), $0.05 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $48.3 million versus the consensus estimate of $45.81 million.

For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS
• Bath & Body Works rises as Citi upgrades stock ahead of earnings